高危前列腺癌盆腔放疗的晚期泌尿毒性及生活质量:POP-RT随机3期试验的剂量-效应关系
POP-RT 3期随机试验比较全盆腔放疗与仅前列腺放疗在高危和极高危前列腺癌中的晚期泌尿毒性及膀胱剂量-效应关系。中位随访75个月,全盆腔放疗与仅前列腺放疗的累积晚期泌尿CTCAE 3级毒性低且相似(5.2% vs 4.1%,P = .49),2级毒性为31.3% vs 22.7%(P = .12),各症状累积发生率及生活质量评分两组相似,多因素分析未发现与晚期泌尿毒性显著相关的因素。
要点
- 全盆腔放疗与仅前列腺放疗的累积晚期泌尿CTCAE 3级毒性低且相似(5.2% vs 4.1%,P = .49)。
- 累积晚期泌尿CTCAE 2级毒性两组为31.3% vs 22.7%(P = .12),各症状累积发生率相似。
- 多因素分析未发现与晚期泌尿毒性显著相关的因素,两组生活质量评分相似。
核心结论
- 长期随访中,全盆腔放疗导致的累积3级泌尿毒性低(约5%)且与仅前列腺放疗相似,患者报告的生活质量评分两组相似,未发现影响晚期泌尿毒性的致病因素。
研究设计与样本
- POP-RT 3期随机试验,比较全盆腔放疗与仅前列腺放疗在高危和极高危前列腺癌患者中的晚期泌尿毒性及膀胱剂量-效应关系。
- 224例患者中193例有晚期泌尿症状和剂量学的完整合并数据。
- 晚期泌尿毒性及随访期间各症状累积严重程度采用CTCAE 5.0版分级。
- 获批放疗计划中膀胱剂量学以5 Gy递增(V5、V10、V15、V65、V68Gy)与泌尿症状及总体2级及以上毒性进行比较。
- 采用多因素逻辑回归分析检验影响泌尿毒性的潜在因素。
主要发现
- 中位随访75个月,全盆腔放疗与仅前列腺放疗的累积晚期泌尿CTCAE 3级毒性分别为5.2% vs 4.1%(P = .49),2级毒性分别为31.3% vs 22.7%(P = .12)。
- 两组各泌尿症状的累积发生率相似。
- 以诊断时年龄、已知糖尿病、肿瘤分期、试验分组、既往经尿道前列腺切除术、2级及以上急性泌尿毒性、低膀胱剂量(V10Gy)和中度膀胱剂量(V40Gy)进行多因素分析,未发现与晚期泌尿毒性任何显著关联。
- 两组所有症状的泌尿生活质量评分相似。
关键数值与推荐
- 晚期泌尿毒性采用CTCAE 5.0版分级。
- 膀胱剂量学参数包括V5、V10、V15、V65、V68Gy(以5 Gy递增)。
- 多因素分析变量包括诊断时年龄、已知糖尿病、肿瘤分期、试验分组、既往经尿道前列腺切除术、2级及以上急性泌尿毒性、V10Gy和V40Gy。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The POP-RT phase 3 randomized trial showed improved biochemical failure-free survival and metastasis-free survival with whole pelvic radiation therapy versus prostate-only radiation therapy for high and very high-risk prostate cancer, albeit with worse RTOG late urinary toxicity. We report updated late urinary adverse effects and bladder dose-effect relations within this trial. METHODS AND MATERIALS: Late urinary toxicity and the cumulative severity of each symptom during the follow-up period were graded using the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Bladder dosimetry in 5-Gy increments (V5, V10, V15, V65, V68Gy) in the approved radiation therapy plans was compared with urinary symptoms and overall grade 2+ toxicity. Potential factors influencing urinary toxicity were tested using multivariable logistic regression analysis. Updated urinary quality of life (QOL) scores were compared between the trial arms. RESULTS: Complete combined data for late urinary symptoms and dosimetry was available for 193 of 224 patients. At a median follow-up of 75 months, cumulative late urinary CTCAE grade 3 toxicity was low and similar for whole pelvic radiation therapy and prostate-only radiation therapy (5.2% vs 4.1%, P = .49), and grade 2 toxicity was 31.3% versus 22.7%, respectively (P = .12). Cumulative rates of each urinary symptom were similar between both arms. Multivariable analysis with age at diagnosis, known diabetes, tumor stage, trial arm, prior transurethral resection of prostate, grade 2+ acute urinary toxicity, low bladder dose (V10Gy), and moderate bladder dose (V40Gy) did not identify any significant association with late urinary toxicity. Urinary QOL scores was similar between both the arms for all the symptoms. CONCLUSIONS: During long-term follow-up, whole pelvic radiation therapy resulted in low (∼5%) and similar grade 3 cumulative urinary toxicity as prostate-only radiation therapy. The long-term patient-reported QOL scores were similar. No causative factors affecting the late urinary toxicity were identified.
引用
- Maitre P, Maheshwari G, Sarkar J, et al. Late Urinary Toxicity and Quality of Life With Pelvic Radiation Therapy for High-Risk Prostate Cancer: Dose-Effect Relations in the POP-RT Randomized Phase 3 Trial. Int J Radiat Oncol Biol Phys. 2024. PMID: 38552989. doi:10.1016/j.ijrobp.2024.03.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。